CD19 and acute lymphoblastic leukemia: Since the first CD19 chimeric antigen receptor T (CAR-T) cell (Kymriah) was approved by the FDA for R/R acute lymphoblastic leukemia, several CD19 CAR-T cells have been approved by the FDA, including Yescarta, Tecartus, and Breyanzi (13).